18F-FDG-PET-based Radiomics signature predicts MGMT promoter methylation status in primary diffuse glioma

Cancer Imaging

Table 1 Patients’ Characteristics of Primary and Validation Cohorts

Characteristics	Primary cohort (n = 71)			Validation cohort (n = 36)			P
Characteristics	Methylated (n = 39)	Unmethylated (n = 32)	P	Methylated (n = 20)	Unmethylated (n = 16)	P	P
Age (mean ± SD, years)	50.72 ± 14.01	50.50 ± 14.82	0.95	46.70 ± 12.45	58.33 ± 11.95	0.08	0.65
Gender			0.97			0.45	0.84
Male	23	19		10	10
Female	16	13		10	6
Weight (mean ± SD, kg)	67.24 ± 12.36	64.20 ± 10.11	0.27	69.05 ± 14.74	66.28 ± 9.56	0.50	0.45
Metabolic Pattern			0.20			0.02	0.34
Cystic	23	14		15	6
Solid	16	18		5	10
WHO Grading			0.05			0.08	0.11
Low Grade Glioma	13	2		11	2
High Grade Glioma	26	30		9	14
SUVmax	9.18 ± 4.05	10.51 ± 4.45	0.20	9.89 ± 4.11	7.84 ± 3.28	0.11	0.33
SUVmean	4.00 ± 2.10	4.60 ± 1.86	0.22	4.31 ± 2.01	3.40 ± 1.59	0.14	0.36

Abbreviations: SD Standard deviation, WHO World Health Organization, SUV Standard uptake value
Note: Chi-Square or Fisher Exact tests, as appropriate, were used to compare the differences in categorical variables, while the independent sample t-test was used to compare the differences in age

ISSN: 1470-7330